These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 28174354

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [Abstract] [Full Text] [Related]

  • 3. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients.
    Canaud B, Polito-Bouloux C, Garred LJ, Rivory JP, Donnadieu P, Taib J, Florence P, Mion C.
    Am J Kidney Dis; 1990 Feb; 15(2):169-75. PubMed ID: 2301388
    [Abstract] [Full Text] [Related]

  • 8. [Hemoglobin levels in hemodialysis patients treated with epoetin: a Brazilian experience].
    Ammirati AL, Watanabe R, Aoqui C, Draibe SA, Carvalho AB, Abensur H, Drumond SS, Moreira J, Bevilacqua JL, Silva AC, Tatsch F, Canziani ME.
    Rev Assoc Med Bras (1992); 2010 Feb; 56(2):209-13. PubMed ID: 20498997
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
    Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J.
    Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V, Mukherjee S, Kosuri R, Dumler F.
    Am J Ther; 2010 Nov; 17(5):469-75. PubMed ID: 19770634
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
    Raymond CB, Collins DM, Bernstein KN, Skwarchuk DE, Vercaigne LM.
    Nephron Clin Pract; 2006 Nov; 102(3-4):c88-92. PubMed ID: 16282700
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C, Blumberg A.
    Schweiz Med Wochenschr; 1990 Feb 17; 120(7):217-20. PubMed ID: 2309110
    [Abstract] [Full Text] [Related]

  • 19. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T, Nishizawa Y, Nakazono H, Asai M, Yamashita H, Sasaki A, Yamashita T, Yamashita K, Shigemoto K, Harada S, Mizuiri S.
    Ther Apher Dial; 2013 Oct 17; 17(5):498-503. PubMed ID: 24107278
    [Abstract] [Full Text] [Related]

  • 20. PDpoietin in comparison with Eprex in treatment of anemic patients on hemodialysis.
    Argani H, Ossareh S, Tabiban S, Ganji MR, Nafar M, Abdi E, Alipour Abedi B.
    Iran J Kidney Dis; 2009 Jul 17; 3(3):145-50. PubMed ID: 19617663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.